With advanced gene testing, we've figured out how readily antidepressants reach the brain.
watch the video
doctor briefing
We have the first positive RCT clinical trial. Evidence indicates gene guided treatment can double your odds of recovery.
read the study
Read the concordance study showing CNSDose has over 85% accuracy.
read the study
To celebrate the culmination of the four-month TMCx accelerator program, 22 digital health startups showcased the progress they have made, and what they have planned for the future. CNSDose offers a genomic solution to fast-track finding the right antidepressant. read more
Three Australian start-up companies have just returned from a four-month stay at the Texas Medical Center (TMC) — the largest medical centre in the world. With an extensive campus of 21 hospitals, 50 non-profit organisations and eight academic and research institutions, TMC concentrates its operations and research on genomics, regenerative medicine, innovation, clinical trials and health policies. read more
CNSDose is a genetically drive, clinically proven, decision support tool that helps avoid the lengthy trial and error process by finding the right antidepressant faster. CNSDose speeds recovery and reduces side effects for patients. read more
